Action APPAD HERON THERAPEUTICS INC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Heron Therapeutics Inc OTC Bulletin Board

Actions

APPAD

US4277461020

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product under the Proposed 2025 Non-Opioid Policy for Pain Relief under the OPPS and the ASC Payment System
AQ
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
PR
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics : Investor Day Presentation
PU
Heron Therapeutics: Q1 Earnings Snapshot
AQ
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
PR
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
PR
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
PR
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
PR
Heron Therapeutics : Q4 2023 Earnings Call Presentation
PU
Heron Therapeutics : Q4 2023 Earnings Call Presentation
PU
Heron Therapeutics: Q4 Earnings Snapshot
AQ
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
PR
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
PR
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
AQ
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
PR
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
AQ
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
PR
Heron Therapeutics: Q3 Earnings Snapshot
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HRTX
  4. Action APPAD
  5. Actualités Heron Therapeutics Inc
  6. Communiqués